Neuronetics
Market Cap
US$190.0m
Last Updated
2019/09/21 00:22 UTC
Data Sources
Company Financials +
Executive Summary
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally.
Snowflake
Fundamentals
Adequate balance sheet and overvalued.
Risks
- Neuronetics has significant price volatility in the past 3 months.
Similar Companies
Share Price & News
How has Neuronetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-9.0%
STIM
1.1%
US Medical Equipment
-0.6%
US Market
1 Year Return
-70.0%
STIM
9.9%
US Medical Equipment
0.6%
US Market
STIM underperformed the Medical Equipment industry which returned 9.5% over the past year.
STIM underperformed the Market in United States of America which returned 1.1% over the past year.
Share holder returns
| STIM | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.0% | 1.1% | -0.6% |
| 30 Day | 5.2% | 0.6% | 2.2% |
| 90 Day | -19.1% | 2.9% | 1.1% |
| 1 Year | -70.0%-70.0% | 10.8%9.9% | 2.9%0.6% |
| 3 Year | n/a | 70.1%64.9% | 44.6%35.2% |
| 5 Year | n/a | 138.9%111.8% | 61.9%44.2% |
Price Volatility Vs. Market
How volatile is Neuronetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Who Has Been Selling Neuronetics, Inc. (NASDAQ:STIM) Shares?1 month ago | Simply Wall St
Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?2 months ago | Simply Wall St
Some Neuronetics (NASDAQ:STIM) Shareholders Have Copped A Big 51% Share Price DropValuation
Is Neuronetics undervalued based on future cash flows and its price relative to the stock market?
3.17x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Neuronetics to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Neuronetics to establish if it is available at substantial discount.
Price Based on Earnings
Neuronetics is loss making, we can't compare its value to the US Medical Equipment industry average.
Neuronetics is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Neuronetics, we can't assess if its growth is good value.
Price Based on Value of Assets
Neuronetics is good value based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Neuronetics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?
6.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Neuronetics's revenue is expected to grow by 18% yearly, however this is not considered high growth (20% yearly).
Neuronetics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Neuronetics's revenue growth is expected to exceed the United States of America market average.
Unable to compare Neuronetics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare Neuronetics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Neuronetics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Neuronetics performed over the past 5 years?
-18.7%
Last years earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Neuronetics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
Unable to compare Neuronetics's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Neuronetics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Neuronetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Neuronetics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Neuronetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Neuronetics's financial position?
Financial Position Analysis
Neuronetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Neuronetics's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Neuronetics's level of debt (51.4%) compared to net worth is high (greater than 40%).
Unable to establish if Neuronetics's debt level has increased without past 5-year debt data.
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 3.3x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Neuronetics has sufficient cash runway for more than 3 years based on current free cash flow.
Neuronetics has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 39.7% each year.
Next Steps
Dividend
What is Neuronetics's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Neuronetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Neuronetics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Neuronetics has not reported any payouts.
Unable to verify if Neuronetics's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Neuronetics has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Neuronetics's salary, the management and board of directors tenure and is there insider trading?
2.2yrs
Average management tenure
CEO
Chris Thatcher (54yo)
4.8yrs
Tenure
US$1,179,548
Compensation
Mr. Christopher A. Thatcher, also known as Chris, has been the Chief Executive Officer and President of Neuronetics, Inc since December 2014. Mr. Thatcher served as the President of Corporate Initiatives a ...
CEO Compensation Analysis
Chris's remuneration is about average for companies of similar size in United States of America.
Chris's compensation has increased whilst company is loss making.
Management Age and Tenure
2.2yrs
Average Tenure
51.5yo
Average Age
The tenure for the Neuronetics management team is about average.
Board Age and Tenure
6.2yrs
Average Tenure
57.5yo
Average Age
The tenure for the Neuronetics board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer & VP |
| Shares | 3,685 |
| Max Price | US$14.53 |
| Entity | Individual |
| Role | Chief Accounting Officer Executive Officer |
| Shares | 8,032 |
| Max Price | US$14.90 |
| Entity | Individual |
| Role | Chief Accounting Officer Executive Officer |
| Shares | 563 |
| Max Price | US$15.40 |
Ownership Breakdown
Management Team
Peter Donato (49yo)
Executive Officer
- Tenure: 0yrs
- Compensation: US$585.23k
Chris Thatcher (54yo)
CEO, President & Director
- Tenure: 4.8yrs
- Compensation: US$1.18m
Steve Furlong
CFO & Company Secretary
- Tenure: 0.2yrs
Greg Harper (58yo)
Vice President of Research & Development
- Tenure: 3yrs
- Compensation: US$460.69k
Daniel Guthrie (42yo)
Chief Commercial Officer & VP
- Tenure: 1.3yrs
- Compensation: US$1.94m
Board Members
Glenn Muir (60yo)
Director
- Tenure: 2.2yrs
- Compensation: US$55.63k
Brian Farley (62yo)
Chairman
- Tenure: 8.7yrs
- Compensation: US$118.28k
Steve Campe (54yo)
Director
- Tenure: 6.7yrs
- Compensation: US$53.13k
Wilf Jaeger (64yo)
Director
- Tenure: 14.3yrs
- Compensation: US$53.13k
Cheryl Blanchard (55yo)
Independent Director
- Tenure: 0.6yrs
Chris Thatcher (54yo)
CEO, President & Director
- Tenure: 4.8yrs
- Compensation: US$1.18m
Company Information
Neuronetics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Neuronetics, Inc.
- Ticker: STIM
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$190.021m
- Shares outstanding: 18.48m
- Website: https://www.neurostar.com
Number of Employees
Location
- Neuronetics, Inc.
- 3222 Phoenixville Pike
- Malvern
- Pennsylvania
- 19355
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| STIM | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Jun 2018 |
| NRC | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2018 |
Biography
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The compa ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/21 00:22 |
| End of Day Share Price | 2019/09/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.